Freeslate Integrates the DropSense96 for Biologics Quantification on its Biologics Formulation System

Share Article

The combination of the DropSense96 with the Core Module 3 platform enables rapid screening and preformulation of biotherapeutics on a single platform

News Image
The full automation of the DropSense96 with Freeslate’s Biologics Formulation System allows users to dramatically increase the throughput of their analysis.

Freeslate, Inc., the leading provider of high throughput research solutions for biopharmaceutical development, and Trinean NV., the leading provider of microfluidic spectrophotometry platforms, today announced the integration of the DropSense96™ with the CM3 product line for biotherapeutics formulation and optimization.

Based on the CM3 automation platform, the Freeslate Biologics Formulation System offers high throughput formulation, stressing, and analysis. Integration of the DropSense96™ provides CM3 users the ability to quickly determine protein concentration without dilution steps. This increases system accuracy and results in faster workflows.

“The full automation of the DropSense96™ with Freeslate’s Biologics Formulation System allows users to dramatically increase the throughput of their analysis. The ability to prepare, stress, and analyze all in one workflow means greater efficiency and enhanced decision making for our users,” add Philippe Stas, CEO of Trinean. “Working together with the Freeslate teams to optimize the workflows has been very rewarding.”

“With a number of seamless integrations of the DropSense96™ with our platform, we have selected the instrument as our preferred option for quantification of biologics,” said John S. Senaldi, President and CEO of Freeslate. “Its unique design combining speed, minimal sample usage, and an unmet measurement range allows for fast, yet robust quantification of protein samples thereby significantly shortening the screening process in biotherapeutic drug development.”

The Trinean DropSense96™ UV/VIS droplet reader is designed for high throughput analysis of biological samples. Its unique microfluidic 96-well format allows for quantification of samples as small as 2 microliter in a fully automated workflow. The Trinean software toolbox is available for detailed sample QC, workflow integration, and compliance in regulatory environments.

Freeslate’s Lab Execution and Analysis (LEA) software seamlessly manages the entire experimental process from design and execution to data analysis and report sharing. It allows users to design complex experiments quickly using its logical, recipe-oriented approach, and experimental conditions can be linked to analytical data for easy viewing and reporting. Using LEA, third party equipment such as the DropSense96™ plate reader, is fully integrated with Freeslate robotic components and sample data is directly linked to the processing steps and analytical results.

Other standard integrations available with the Biologics Formulation System include fully automated third party instruments such as the dynamic light scatter reader, centrifuge, plate sealer, and shaking incubator and off-deck, semi-automated analytical instruments including UPLC, HPLC, cIEF,and cSDS.

About Trinean

Trinean is a Belgium based instrumentation company, bringing micro-volume molecular spectroscopy to the next level by combining best in class analytical software with a highly standardized read-out platform. Founded in 2006 as a spin-out of the Ghent University, Belgium and Imec Leuven, Belgium, the company commercializes two instruments, the XposeTM for ‘Touch & Go’ biomolecule quantification and the DropSense96™, analyzing up to 96 samples, using microfluidic chips for standardized sample analysis (DropPlates and Xpose Slides). The Trinean platform is complemented with a software toolbox for improved data interpretation and lab-automation. For more information about Trinean, visit

About Freeslate

Freeslate is a privately held company providing laboratory automation products that dramatically improve the productivity and innovation of drug development organizations. For more than a decade, Freeslate has been working with customers to automate complex chemical research processes. Our resulting product line includes solutions for protein and vaccine drug formulation development, small molecule solubility, and polymorph screening and process chemistry. We start with a scientific understanding of our customer’s bottlenecks and utilize our robust and proprietary automation platforms and integrated Lab Execution and Analysis (LEA) software suite to deliver solutions that make a difference. The company is headquartered in Sunnyvale, California, with direct sales and service in North America, Europe, and Asia. For more information, visit

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Mikelle Thatcher
Freeslate, Inc.
+1 (408) 773-4081
Email >
Visit website